<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04889742</url>
  </required_header>
  <id_info>
    <org_study_id>HETERERO</org_study_id>
    <nct_id>NCT04889742</nct_id>
  </id_info>
  <brief_title>Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors</brief_title>
  <acronym>HETERERO</acronym>
  <official_title>Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investiagates deep-regional or superficial hyperthermia to enhance radiotherapy or&#xD;
      chemoradiation in patients that suffer recurrent disease after previous radiotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      patients that present a relapse within the previously irradiated volume can be included in&#xD;
      this trial. These patients will receive re-irradiation according to clinical guidelines and&#xD;
      hyperthermia as study intervention. According to tumor location hyperthermia can either be&#xD;
      performed by microwave or by capacitive devices.&#xD;
&#xD;
      The primary endpoint of this study is non-inferiority of re-irradiation compared to the&#xD;
      initial course of radiotherapy (calculated as time to local failure).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2021</start_date>
  <completion_date type="Anticipated">January 2028</completion_date>
  <primary_completion_date type="Anticipated">January 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients will receive additional hyperthermia according to physicians´choice as a radiosensitizer to standard of care re-irradiation or re-chemoradiation.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local tumor recurrence</measure>
    <time_frame>3 years</time_frame>
    <description>Local tumor recurrence of re-irradiated lesions, calculated with the Kaplan-Meier estimates. Local recurrence after hyperthermic re-irradiation will be compared to time-to recurrence after initial treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>Overall survival after start of re-irradiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>Progression-free survival after start of re-irradiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from distant metastases</measure>
    <time_frame>3 years</time_frame>
    <description>Freedom from distant metastases after start of re-irradiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported quality of Life</measure>
    <time_frame>3 years</time_frame>
    <description>patient reported quality of life measured by the EORTC qlq-c30 questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Recurrent Cancer</condition>
  <condition>Prostate Cancer</condition>
  <condition>Cervical Cancer</condition>
  <condition>Anal Cancer</condition>
  <condition>Sarcoma</condition>
  <condition>Rectal Cancer</condition>
  <condition>Neuroendocrine Tumors</condition>
  <condition>Esophageal Cancer</condition>
  <condition>Pancreas Cancer</condition>
  <condition>Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Hyperthermia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 6-8 treatments additional loco-regional hyperthermia concurrent to re-irradiation. Hyperthermia will start on the third day of fractionated radiotherapy and will be given twice per week. According to site of recurrent disease either deep-regional, capacitive or superficial hyperthermia devices may be used.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>loco-regional hyperthermia</intervention_name>
    <description>loco-regional hyperthermia by the use of microwave, capacitive, or superficial hyperthermia devices.</description>
    <arm_group_label>Hyperthermia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  prior radiotherapy of the treatment side with a treatment dose &gt; 30 Gray (Gy) EQD2&#xD;
             (calculated with alpha/beta value of 9)&#xD;
&#xD;
          -  local/ regional / or oligometastatic tumor recurrence. Maximum number of three&#xD;
             macroscopic tumor lesions with at least one of them receiving prior radiotherapy&#xD;
&#xD;
          -  macroscopic tumor recurrence&#xD;
&#xD;
          -  side of recurrence is amenable to hyperthermia (abdomen, pelvis, extremities, spine,&#xD;
             cervical lymphnodes)&#xD;
&#xD;
          -  planned re-irradiation dose of at least 40 Gy EQD2 (calculated with alpha/beta value&#xD;
             of 9)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &gt;3 macroscopic tumor lesion&#xD;
&#xD;
          -  brain metastases&#xD;
&#xD;
          -  recurrence is amenable to local ablative radiotherapy (brachytherapy or stereotactic&#xD;
             radiotherapy)&#xD;
&#xD;
          -  recurrence region is not amenable to hyperthermia (lung, liver, mediastinum)&#xD;
&#xD;
          -  contraindications for hyperthermia (serious cariovascular disease, ICD or larger&#xD;
             implants at the treatment site)&#xD;
&#xD;
          -  psychiatric disorders that impede proper informed consent&#xD;
&#xD;
          -  serious comorbidities with very limited prognosis quo ad vitam&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sebastian Zschaeck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sebastian Zschaeck, MD</last_name>
    <phone>+4930450650764</phone>
    <email>sebastian.zschaeck@charite.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinik für Radioonkologie und Strahlentherapie</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Zschaeck, M.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 12, 2021</study_first_submitted>
  <study_first_submitted_qc>May 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2021</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Sebastian Zschaeck</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>re-irradiation</keyword>
  <keyword>hyperthermia</keyword>
  <keyword>local recurrence</keyword>
  <keyword>hyperthermic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Anus Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Hyperthermia</mesh_term>
    <mesh_term>Fever</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

